Synopsis
Synopsis
0
JDMF
0
EU WC
0
KDMF
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Decaris
2. Dekaris
3. Hydrochloride, Levamisole
4. L-tetramisole
5. Levamisole Hydrochloride
6. Levotetramisole
7. Solaskil
1. 14769-73-4
2. Levamisol
3. L-tetramisole
4. Ketrax
5. Wormicid
6. Lepuron
7. Levomysol
8. Levamisolum
9. (s)-6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b]thiazole
10. Levamisol [inn-spanish]
11. Levamisolum [inn-latin]
12. (-)-tetramisole
13. (6s)-6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole
14. (s)-(-)-levamisole
15. Tcmdc-125847
16. Vermisol 150
17. Dl-tetramisole
18. L-tetramisol
19. Levamisole (inn)
20. Tetramisole, (s)-
21. (6s)-6-phenyl-2h,3h,5h,6h-imidazo[2,1-b][1,3]thiazole
22. Imidazo(2,1-b)thiazole, 2,3,5,6-tetrahydro-6-phenyl-, (s)-
23. Chembl1454
24. Chebi:6432
25. (6s)-6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b]thiazole
26. 14769-73-4 (free Base)
27. Levamisole [inn]
28. Imidazo[2,1-b]thiazole, 2,3,5,6-tetrahydro-6-phenyl-, (6s)-
29. 2880d3468g
30. Levamisole [inn:ban]
31. Levovermax
32. Totalon
33. 49548-36-9
34. L-2,3,5,6-tetrahyro-6-phenylimidazo(2,1-b)thiazole
35. Imidazo(2,1-b)thiazole, 2,3,5,6-tetrahydro-6-phenyl-, (6s)-
36. (-)-tetramisole Hydrochloride
37. L(-)-levamisole
38. Ketrax (tn)
39. Nsc177023
40. Einecs 238-836-5
41. Mfcd00792481
42. Unii-2880d3468g
43. Levamisol 100 Microg/ml In Acetonitrile
44. (-)-levamisole
45. Spectrum_001609
46. Levamisole [mi]
47. (s)-(-)-tetramisole
48. Prestwick0_000182
49. Prestwick1_000182
50. Prestwick2_000182
51. Spectrum2_000865
52. Spectrum3_000962
53. Spectrum4_001078
54. Spectrum5_001645
55. Levamisole [vandf]
56. P00039
57. Levamisole [mart.]
58. (-)-6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b]thiazole
59. (s)-2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole
60. Levamisole [who-dd]
61. Lopac0_000690
62. Schembl19227
63. Bspbio_002563
64. Kbiogr_001436
65. Kbioss_002089
66. Cid_68628
67. Bidd:gt0372
68. Divk1c_000667
69. Spbio_000909
70. Spbio_002024
71. Gtpl7210
72. Levamisole [green Book]
73. Dtxsid4023206
74. Kbio1_000667
75. Kbio2_002089
76. Kbio2_004657
77. Kbio2_007225
78. Kbio3_001783
79. Ninds_000667
80. Hms2090o04
81. Zinc119839
82. Hy-a0106
83. Bdbm50241179
84. Dl-429
85. Levamisol 100 Microg/ml In Methanol
86. Akos001637203
87. Ccg-204775
88. Cs-w009271
89. Db00848
90. Ds-4066
91. Sdccgsbi-0050668.p004
92. Idi1_000667
93. Ncgc00162225-02
94. Ncgc00162225-03
95. Ncgc00162225-04
96. Ncgc00162225-05
97. Ncgc00162225-08
98. Ncgc00162225-14
99. Ac-18929
100. Nci60_001476
101. Sbi-0050668.p003
102. C07070
103. C72809
104. D08114
105. Ab00053661-07
106. Ab00053661-08
107. Ab00053661_09
108. Ab00053661_10
109. A808675
110. Q417097
111. Brd-k73107279-003-03-4
112. 2,3,5,6-tetrahydro-6-phenyl-imidazo[2,1-b]thiazole, (s)-
113. (-)-6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole
114. 6-phenyl-2,3,5,6-tetrahydro-imidazo[2,1-b]thiazole (levamisole)
115. 6-phenyl-2,3,5,6-tetrahydro-imidazo[2,1-b]thiazole(levamisole)
116. 6-phenyl-2,3,5,6-tetrahydro-imidazo[2,1-b]thiazole(tetramisole)
117. Levamisole;6-phenyl-2,3,5,6-tetrahydro-imidazo[2,1-b]thiazole
118. Tetramisole;6-phenyl-2,3,5,6-tetrahydro-imidazo[2,1-b]thiazole
119. (-)-levamisole Hydrochloride Solution, 1.0 Mg/ml In Methanol (as Free Base), Ampule Of 1 Ml, Certified Reference Material
| Molecular Weight | 204.29 g/mol |
|---|---|
| Molecular Formula | C11H12N2S |
| XLogP3 | 1.8 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 1 |
| Exact Mass | 204.07211956 g/mol |
| Monoisotopic Mass | 204.07211956 g/mol |
| Topological Polar Surface Area | 40.9 Ų |
| Heavy Atom Count | 14 |
| Formal Charge | 0 |
| Complexity | 246 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
For adjuvant treatment in combination with fluorouracil after surgical resection in patients with Dukes' stage C colon cancer. Also used to treat malignant melanoma and head/neck cancer.
Levamisole is a synthetic imidazothiazole derivative that has been widely used in treatment of worm infestations in both humans and animals. As an anthelmintic, it probably works by targeting the nematode nicotinergic acetylcholine receptor. As an immunomodulator, it appears that Levamisole is an immunostimulant which has been shown to increase NK cells and activated T-cells in patients receiving this adjuvantly along with 5FU for Stage III colon cancer.
Adjuvants, Immunologic
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)
Antirheumatic Agents
Drugs that are used to treat RHEUMATOID ARTHRITIS. (See all compounds classified as Antirheumatic Agents.)
Antinematodal Agents
Substances used in the treatment or control of nematode infestations. They are used also in veterinary practice. (See all compounds classified as Antinematodal Agents.)
P - Antiparasitic products, insecticides and repellents
P02 - Anthelmintics
P02C - Antinematodal agents
P02CE - Imidazothiazole derivatives
P02CE01 - Levamisole
Absorption
Levamisole is rapidly absorbed (2 hours) from the gastrointestinal tract.
Primarily hepatic (extensive) with both active and inactive metabolites.
4.4-5.6 hours (biphasic)
The mechanism of action of levamisole as an antiparasitic agent appears to be tied to its agnositic activity towards the L-subtype nicotinic acetylcholine receptors in nematode muscles. This agonistic action reduces the capacity of the males to control their reproductive muscles and limits their ability to copulate. The mechanism of action of Levamisole as an anticancer drug in combination with fluorouracil is unknown. The effects of levamisole on the immune system are complex. The drug appears to restore depressed immune function rather than to stimulate response to above-normal levels. Levamisole can stimulate formation of antibodies to various antigens, enhance T-cell responses by stimulating T-cell activation and proliferation, potentiate monocyte and macrophage functions including phagocytosis and chemotaxis, and increase neutrophil mobility, adherence, and chemotaxis.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
71
PharmaCompass offers a list of Levamisole API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Levamisole manufacturer or Levamisole supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Levamisole manufacturer or Levamisole supplier.
PharmaCompass also assists you with knowing the Levamisole API Price utilized in the formulation of products. Levamisole API Price is not always fixed or binding as the Levamisole Price is obtained through a variety of data sources. The Levamisole Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Ergamisol manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ergamisol, including repackagers and relabelers. The FDA regulates Ergamisol manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ergamisol API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Ergamisol manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Ergamisol supplier is an individual or a company that provides Ergamisol active pharmaceutical ingredient (API) or Ergamisol finished formulations upon request. The Ergamisol suppliers may include Ergamisol API manufacturers, exporters, distributors and traders.
click here to find a list of Ergamisol suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Ergamisol DMF (Drug Master File) is a document detailing the whole manufacturing process of Ergamisol active pharmaceutical ingredient (API) in detail. Different forms of Ergamisol DMFs exist exist since differing nations have different regulations, such as Ergamisol USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Ergamisol DMF submitted to regulatory agencies in the US is known as a USDMF. Ergamisol USDMF includes data on Ergamisol's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Ergamisol USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Ergamisol suppliers with USDMF on PharmaCompass.
A Ergamisol CEP of the European Pharmacopoeia monograph is often referred to as a Ergamisol Certificate of Suitability (COS). The purpose of a Ergamisol CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Ergamisol EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Ergamisol to their clients by showing that a Ergamisol CEP has been issued for it. The manufacturer submits a Ergamisol CEP (COS) as part of the market authorization procedure, and it takes on the role of a Ergamisol CEP holder for the record. Additionally, the data presented in the Ergamisol CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Ergamisol DMF.
A Ergamisol CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Ergamisol CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Ergamisol suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Ergamisol as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Ergamisol API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Ergamisol as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Ergamisol and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Ergamisol NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Ergamisol suppliers with NDC on PharmaCompass.
Ergamisol Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ergamisol GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ergamisol GMP manufacturer or Ergamisol GMP API supplier for your needs.
A Ergamisol CoA (Certificate of Analysis) is a formal document that attests to Ergamisol's compliance with Ergamisol specifications and serves as a tool for batch-level quality control.
Ergamisol CoA mostly includes findings from lab analyses of a specific batch. For each Ergamisol CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ergamisol may be tested according to a variety of international standards, such as European Pharmacopoeia (Ergamisol EP), Ergamisol JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ergamisol USP).
